BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Long R, Drawbaugh ML, Davis CM, Goodlett CR, Williams JR, Roper RJ. Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome. Complement Ther Med 2019;45:234-41. [PMID: 31331567 DOI: 10.1016/j.ctim.2019.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Rondal JA. Down syndrome: A curative prospect? AIMS Neurosci 2020;7:168-93. [PMID: 32607419 DOI: 10.3934/Neuroscience.2020012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Rondal JA. From the lab to the people: major challenges in the biological treatment of Down syndrome. AIMS Neurosci 2021;8:284-94. [PMID: 33709029 DOI: 10.3934/Neuroscience.2021015] [Reference Citation Analysis]
3 Martínez Cué C, Dierssen M. Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome. Preclinical Research in Down Syndrome: Insights for Pathophysiology and Treatments. Elsevier; 2020. pp. 269-302. [DOI: 10.1016/bs.pbr.2019.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]